These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2525529)

  • 21. Therapy of serious gram-positive infections with teicoplanin.
    Davies AJ; Stone JM; Synott M
    Drugs Exp Clin Res; 1989; 15(1):29-31. PubMed ID: 2526010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Teicoplanin in the treatment of gram-positive-bacterial endocarditis.
    Martino P; Venditti M; Micozzi A; Brandimarte C; Gentile G; Santini C; Serra P
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1329-34. PubMed ID: 2529815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of teicoplanin in hemodialysis patients.
    Höffler D; Koeppe P; Naumann E; Lang E; Sörgel F
    Infection; 1991; 19(5):324-7. PubMed ID: 1839299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.
    Greenberg RN
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2392-7. PubMed ID: 2150908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients.
    Lemerle S; de La Rocque F; Lamy R; Fremaux A; Bernaudin F; Lobut JB; Reinert P
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():113-6. PubMed ID: 2965122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group, USA.
    LeFrock JL; Ristuccia AM; Ristuccia PA; Quenzer RW; Haggerty PG; Allen JE; Lettau LA; Schwartz R; Appleby D
    Eur J Surg Suppl; 1992; (567):9-13. PubMed ID: 1381644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous or intramuscular teicoplanin once daily for skin and soft-tissue infections.
    Edelstein HE; Oster SE; Chirurgi VA; Karp RA; Cassano KB; McCabe RE
    DICP; 1991 Sep; 25(9):914-8. PubMed ID: 1835223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Teicoplanin for therapy of gram-positive infections in neutropenic patients.
    Verhagen C; De Pauw BE
    Int J Clin Pharmacol Res; 1987; 7(6):491-8. PubMed ID: 2964418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Efficacy and tolerance of teicoplanin in postoperative infections caused by gram-positive microorganisms].
    Alberghina A; Romeo B; Pessione E; Mauri A; Enrichens F; Sciascia C; Olivero G
    Minerva Chir; 1987 Sep; 42(17):1339-45. PubMed ID: 2959879
    [No Abstract]   [Full Text] [Related]  

  • 30. [The use of teicoplanin in neutropenic patients: values and limits].
    Espinouse D; Chomarat M
    Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):552-6. PubMed ID: 2143573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical evaluation of efficacy, pharmacokinetics, and safety of teicoplanin for serious gram-positive infections.
    Bibler MR; Frame PT; Hagler DN; Bode RB; Staneck JL; Thamlikitkul V; Harris JE; Haregewoin A; Bullock WE
    Antimicrob Agents Chemother; 1987 Feb; 31(2):207-12. PubMed ID: 2952062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dalbavancin: an investigational glycopeptide.
    Guay DR
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):845-52. PubMed ID: 15566329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Microbiological-clinical study on the efficacy of a new antibiotic: teicoplanin].
    Martinetto P; Gariglio M; Malcangi A; Cavallo GP
    G Batteriol Virol Immunol; 1985; 78(1-6):86-94. PubMed ID: 2943627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Teicoplanin: Part 1. An evaluation of the concentrations seen in serum and the subcutaneous fat of the relatively ischaemic lower limb following a single intravenous bolus.
    Antrum RM; Bibby SR; Ramsden CH; Kester RC
    Drugs Exp Clin Res; 1989; 15(1):21-3. PubMed ID: 2526008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Options and limitations of teicoplanin in febrile granulocytopenic patients.
    De Pauw BE; Novakova IR; Donnelly JP
    Br J Haematol; 1990 Dec; 76 Suppl 2():1-5. PubMed ID: 2149042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis.
    Bowley JA; Pickering SJ; Scantlebury AJ; Ackrill P; Jones DM
    J Antimicrob Chemother; 1988 Jan; 21 Suppl A():133-9. PubMed ID: 2965125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections.
    Cruciani M; Navarra A; Di Perri G; Andreoni M; Danzi MC; Concia E; Bassetti D
    Clin Infect Dis; 1992 Aug; 15(2):285-9. PubMed ID: 1387805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
    Dorr MB; Jabes D; Cavaleri M; Dowell J; Mosconi G; Malabarba A; White RJ; Henkel TJ
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii25-30. PubMed ID: 15750034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oritavancin - a new semisynthetic lipoglycopeptide agent to tackle the challenge of resistant gram positive pathogens.
    Das B; Sarkar C; Schachter J
    Pak J Pharm Sci; 2013 Sep; 26(5):1045-55. PubMed ID: 24035967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spanish experience with teicoplanin.
    Fernández-Guerrero M; Gobernado M; Ariza J; Williams A
    Scand J Infect Dis Suppl; 1990; 72():38-44. PubMed ID: 2151066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.